A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase III study ARIEL3 of rucaparib maintenance treatment
Jonathan A. Ledermann,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W. Holloway,M. Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,T. Cameron,Lara Maloney,Sandra Goble,Robert L. Coleman +19 more
Journal ArticleDOI
Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer
Alexandre Sauriol,Euridice Carmona,Molly Lizabeth Udaskin,Nikolina Radulovich,Kim Leclerc-Desaulniers,Robert Rottapel,Amit M. Oza,Stephanie Lheureux,Diane Provencher,Anne-Marie Mes-Masson +9 more
TL;DR: In this paper , the authors explored a novel therapeutic option to counter the acquired PARPi resistance, combining PARPi and inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Journal ArticleDOI
941TiPENGOT-OV16/NOVA: A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH PARP-INHIBITOR NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER
M Mirza,Bradley J. Monk,Jonathan A. Ledermann,Amit M. Oza,J. M. Del Campo,Jonathan S. Berek,Sven Mahner,Robert M. Wenham,Ignace Vergote,Michel Fabbro,Christian Marth,Anne Dørum,Domenica Lorusso,Dionyssios Katsaros,Ilan Bruchim,Susanne Malander,Jørn Herrstedt,Shefali Agarwal,Robert E. Martell,Ursula A. Matulonis +19 more
TL;DR: The aim is to evaluate efficacy of niraparib as maintenance therapy assessed by the prolongation of progression free survival (PFS) and bridge the centralized BRCA mutation test method to the candidate companion diagnostic test.
Journal ArticleDOI
Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients.
Neda Stjepanovic,Philippe L. Bedard,Amit M. Oza,Blaise A. Clarke,Monika K. Krzyzanowska,Raymond Woo-Jun Jang,Neesha C. Dhani,Natasha B. Leighl,Abha A. Gupta,Christine Elser,Jeanna McCuaig,Melyssa Aronson,Spring Holter,Kara Semotiuk,Lailah Ahmed,Lisa Wang,Tracy Stockley,Suzanne Kamel-Reid,Lillian L. Siu,Raymond H. Kim +19 more
TL;DR: Next generation sequencing of tumor DNA is used to match precision cancer therapies to identify a previously unrecognized hereditary cancer syndrome (HCS) and patients’ preferences in learning about HCSs discovered through an institutional somatic NGS program are analyzed.
Journal ArticleDOI
Clinical outcome of sequential chemotherapy after immune checkpoint inhibitors in advanced ovarian cancer.
Luisa Bonilla,Amit M. Oza,Stephanie Lheureux,Sam Saibil,Shiyi Chen,Yeh Chen Lee,Diana Gray,Ilaria Colombo,Ainhoa Madariaga,Neesha C. Dhani,Gita Bhat,Valerie Bowering,Swati Garg,Daniel Yokom,Sunu Cyriac,Marcus O. Butler +15 more
TL;DR: The once-weekly treatment of ovarian cancer with immune checkpoint inhibitors with or without immunomodulation through check point inhibition for at least 12 months prolongs survival and reduces the need for chemotherapy.